An interventional study of Healthy diet based on NNR2023 and Control/waiting-list in Rheumatoid Arthritis (RA), sponsored by Vastra Gotaland Region. Enrolling by invitation at 1 site in Sweden. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region — 2 open to participants now, 5 under way, none of them phase 3. Arthritis, Rheumatoid · Vastra Gotaland Region.
Among the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region, this one is the only one that started in 2025, is one of 5 with no phase, and was the 11th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region are open now, in 1 country. Recruiting first, the newest first:
Vastra Gotaland Region · Sites in Sweden
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 81 across the 6 interventional studies, 2,500 across the 5 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background: Individuals with Rheumatoid Arthritis (RA) often experience persistent symptoms such as pain and stiffness despite modern pharmacological treatments. They also have an increased risk of cardiovascular disease. Elevated risk factors for cardiovascular disease limit the options for some symptom-relieving medications, making a reduction in these risk factors highly desirable. Diet has been shown to reduce several of these factors, but the scientific evidence for rheumatoid arthritis is limited, and thus tailored dietary advice is lacking.
Objective: The purpose of the NUTRA study is to evaluate the effect of a diet that follows the updated Nordic Nutrition Recommendations (2023) on disease activity and cardiovascular risk factors in individuals with diagnosed RA. Specifically, the study will analyze the impact of the diet on clinically relevant markers such as blood pressure, lipid profile, inflammatory markers, and body composition.
Study Plan: The study will include about 120 patients, and participants will be randomized into either an immediate 3-month diet intervention following the Nordic Nutrition recommendations or a waitinglist control group, that will start with the diet intervention after three months. The intervention diet, will be added as a complementary treatment to the medications the patients are already taking. Participants will receive menus, recipes and some foods for three months, followed by self-maintenance of the diet. Clinical markers will be evaluated before and after the intervention/control periods and six months after ending their intervention period. Primary outcome is ApoB.
The NUTRA study aims to generate evidence to guide the design of dietary interventions for patients with rheumatoid arthritis. By understanding the potential role of diet in reducing both disease activity and cardiovascular risk, the study may contribute to improved treatment strategies for this challenging patient group.
NUTRA population and recruitment. Approximately 120 women and men aged 18-85 years with diagnosed RA will be recruited in the Gothenburg region. Approximately 42-48 evaluable participants per randomized group provide 80% power to detect a 15% between-group difference in ApoB after three months at a two-sided α=0.05. Stable treatment and no planned changes in antirheumatic or lipid-affecting medication during the primary period limit pharmacological confounding. Recruitment follows established rheumatology pathways; detailed eligibility criteria are governed by the approved protocol.
Randomization and intervention. Participants are randomized to an immediate three-month intervention or a waiting-list control for three months before receiving the same dietary intervention. The intervention follows NNR2023 and combines food provision with structured, individualized support to facilitate sustainable change. The waiting-list design preserves a randomized comparison while ensuring that all participants are offered the intervention.
Data collection. Baseline and three-month assessments include fasting blood samples, clinical phenotype, blood pressure, joint examination, body composition by dual-energy X-ray absorptiometry, physical function and quality-of-life questionnaires, weighed dietary records and a Food Frequency Questionary (FFQ). Adherence is evaluated from dietary data and selected biomarkers. Samples are stored for metabolomics and inflammatory profiling. The simplified six-month after intervention end follow-up consists of fasting routine blood lipids only, minimizing participant burden while retaining a clinically meaningful maintenance outcome.
Outcomes and analysis. ApoB is the primary outcome. Secondary outcomes include LDL and HDL cholesterol, triglycerides, total cholesterol, disease activity measured by the Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR), and European Alliance of Associations for Rheumatology (EULAR) response and remission. Olink Target 96 Inflammation characterizes inflammatory profiles; metabolomics supports exploratory response and predictor analyses. The primary analysis follows intention-to-treat principles, comparing randomized groups at three months with baseline adjustment. Mixed-effects models will account for repeated measurements where appropriate. Inflammatory analyses will address multiple testing. Predictor analyses will be exploratory, with model complexity constrained by sample size and internal validation used to assess overfitting.
The criteria were revised on the registry on Oct 23, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diet following the Nordic Nutrition Recommendations 2023
Other: Healthy diet based on NNR2023
Habitual diet for 3 months followed by healthy diet based on NNR2023 for 3 months
Other: Healthy diet based on NNR2023 · Other: Control/waiting-list
Personalized diet- the participants will get individual advice how to adapt their habitual diet to the Nordic Nutrition Recommendations 2023
Habitual diet during the waiting-period/control followed by healthy diet based on NNR2023
Apolipoprotein B
Time frame: 3 months dietary intervention and at 9 months follow up
Patterns of serum inflammatory markers
Olink Target 96 Inflammation panel will be analysed and multivariate method (OPLS-DA) will be used to evaluate changes in the inflammatory markers between intervention and control.
Time frame: 3 months dietary intervention
Remission yes/no
Based on disease activity score -28 joints-erythrocyte sediment rate (DAS28-ESR) and European League Against Rheumatism (EULAR) criteria
Time frame: 3 months dietary intervention
Disease activity DAS28-CRP
based on disease activity score -28 joints-c-reactive protein (DAS28-CRP)
Time frame: 3 months dietary intervention
triacylglycerides
Time frame: 3 months dietary intervention and at 9 months follow up
high density lipoprotein
HDL
Time frame: 3 months dietary intervention and at 9 months follow up
Low density lipoprotein (LDL)
Time frame: 3 months dietary intervention and at 9 months follow up
total cholesterol
Time frame: 3 months dietary intervention and at 9 months follow up
Erythrocyte sediment rate (ESR)
Time frame: 3 months dietary intervention and at 9 months follow up
high sensitive-C-reactive protein (hs-CRP)
Time frame: 3 months dietary intervention and at 9 months follow up
Corticosteroid use
Participants will note the use of corticosteroids. A decrease could indicate less pain. Changes is also important to adjust for in analysis of effects on inflammation markers.
Time frame: 3 months dietary intervention and at 9 months follow up
Physical disability
Based on the questionnaire HAQ THE HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) DISABILITY INDEX (DI) There are 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). Total score is divided to the number of categories and the range of the index is thus 0-3p.
Time frame: 3 months dietary intervention and at 9 months follow up
Quality of life (RAND-SF36)
Self-reported quality of life based on the questionnaire 36-Item Short Form Survey Instrument (SF-36) from RAND (Research and Development- non profit organisation). It taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. Scale is 0-100. Higher score indicates better quality of life.
Time frame: 3 months dietary intervention and at 9 months follow up
Disease activity score DAS28-ESR
Disease activity score based on 28 joints and erythrocyte sediment rate (ESR)
Time frame: 3 months dietary intervention
Body mass index (BMI)
Patients are not advised to actively try to loose weight, but do not have to try to keep their weight either. BMI will be a descriptive measure.
Time frame: 3 months dietary intervention and at 9 months follow up
Patterns of metabolites
Metabolites analysed by NMR or LC-MS/GC-MS for metabolomics studies (changes in patterns of metabolites). This outcome will mainly be used to evaluate compliance to the intervention diet. Metabolite patterns will be compared by multivariate methods such as OPLS-DA. This outcome will also be used at baseline for descriptives of the participants i.e. habitual lifestyle and diet.
Time frame: 3 months dietary intervention
Body composition
Dual x ray absorptiometry (DXA) at baseline and 9 months Descriptive/for adjustment and relative to both diet and eventual changes in physical activity
Time frame: screening only
European League Against Rheumatism (EULAR) criteria for disease activity
Based on Disease Activity Score -28 joints -Erythrocyte sediment rate. This can be used to classify patients as good, moderate or non-responders, using the individual amount of change in the DAS and the DAS value (low, moderate, or high) reached. Classes can be used to explore differences in baseline metabolomics, gut microbiota and body composition.
Time frame: 3 months dietary intervention
Differences in changes in fatty acid patterns in plasma
Fatty acids will be analysed in plasma and patterns of fatty acids will be analysed and changes in fatty acid patterns during intervention and control will be compared with multivariate methods as a marker for compliance to the diets.
Time frame: 3 months dietary intervention
Differences in changes in fatty acid patterns in erythrocytes
Fatty acids will be analysed in erythrocytes and changes in fatty acid patterns during intervention and control will be compared with multivariate methods as a marker for compliance to the diets.
Time frame: 3 months dietary intervention
Plan to share: No — Not eligible according to Swedish law
Started Feb 2025 (actual). Primary completion is estimated for Dec 2028, 46 months after the start.
Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 46 months is above that.
Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.